Antech Launches trūRapid™ FOUR: Simplifying Canine Vector-Borne Disease Screening for Veterinarians
trūRapid™ FOUR is a lateral flow test used to detect canine antibodies to Anaplasma spp., Ehrlichia spp., and Lyme C6 ( Borrelia burgdorferi), as well as heartworm ( Dirofilaria immitis) antigen, using whole blood, serum, or plasma.
Jimmy Barr, DVM, DACVECC, Chief Medical Officer for Mars Petcare's Science & Diagnostics division and Antech, said: 'With its speed, proven reliability, and streamlined workflow, trūRapid™ FOUR offers busy veterinary professionals a simple alternative to current testing protocols and, importantly, provides an affordable choice without compromising quality.'
Key Features of trūRapid™ FOUR include:
Streamlined Workflow: Requires just a few drops of sample, minimizing the need for additional blood draws or sample centrifugation. Eliminates manual snapping; the test reaction begins automatically when the sample and buffer is directly added.
Proven Reliability: Excellent sensitivity and specificity when compared to reference laboratory testing. For Lyme, C6 ensures high specificity, preventing false positives caused by vaccination.
Broad reactivity: E. canis, E. chaffeensis, and E. ewingii; A. phagocytophilum and A. platys.
No refrigeration: Tests can be stored at room temperature for their entire shelf life, saving refrigerator space, simplifying inventory management, and eliminating the need to warm up the test before use.
Eco-Friendly Design: Generates less plastic waste with no need for additional sample handling tubes — just the cartridge and a plastic pipette.
About Antech
Antech is a global veterinary diagnostics company, driven by our passion for innovation that helps veterinarians deliver better animal health outcomes. Our products and services span 90+ reference laboratories around the globe; in-house diagnostic laboratory instruments and consumables, including rapid assay diagnostic products and digital cytology services; local and cloud-based data services; practice information management software and related software and support; veterinary imaging and technology; veterinary professional education and training; and board-certified specialist support services.
SOURCE: Antech
Copyright Business Wire 2025.
PUB: 03/10/2025 08:46 AM/DISC: 03/10/2025 08:47 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 minutes ago
- Business Wire
Wiland Expands MarketSignals™ Platform with Powerful New Brand and Category Signals Capabilities
NIWOT, Colo.--(BUSINESS WIRE)--Wiland, Inc., a leading provider of marketing data and predictive intelligence, today announced the addition of brand and category signals to its rapidly expanding MarketSignals™ platform. This new release brings powerful brand- and category-level insights to marketers seeking to optimize their strategies, conquer competitive challenges, and unlock growth across verticals such as retail, travel, dining, insurance, and more. 'With brand and category signals, we're giving marketers the clearest view yet into what drives consumer choice—insight that transforms targeting, retention, and growth strategies.' — Mike Gingell, CEO, Wiland Share Built from Wiland's immense consumer spending data—comprised of actual transactions from over 80 million individuals—brand and category signals deliver predictive signals for more than 220 top consumer brands and product categories. This expansion introduces granular, brand-specific elements such as purchase propensity, loyalty score, and lifetime value, giving marketers an unprecedented understanding of how their best customers—and their competitors'—behave across the marketplace. Wiland is adding new signals every two weeks and expects to increase coverage to over 500 brands and categories by the end of the year. 'With brand and category signals, we're empowering marketers with the clearest view yet of what drives consumer choice at the brand level,' said Mike Gingell, CEO of Wiland. 'This isn't just about knowing if someone is likely to shop at a specific retailer—it's about understanding the depth of that relationship, whether they're loyal, infrequent, or part of the moveable middle. These signals are transformative for marketers looking to personalize outreach, reduce churn, and drive smarter growth decisions.' Modeled from trillions of dollars in actual spend data, brand and category signals offer predictive insights in key behavioral dimensions—recency, frequency, and monetary value—across both brands and categories. These signals reveal: Who is buying from which brands How often they make purchases How loyal they are—or are not Whether they're currently in-market How much they are likely to spend over time Use cases range from uncovering brand conquesting opportunities and identifying competitive pressures, to segmenting audiences by customer value and loyalty. For example, a major brand can use brand and category signals to understand which of its loyal customers are shopping at competitors—or discover partnership opportunities through adjacencies. Unlike panels or opt-in loyalty data that reflect small slivers of consumer behavior, brand and category signals deliver insights across a vast, modeled universe of actual buyers. It enables brands to eliminate reliance on incomplete or unmatchable raw data and instead integrate high-performing predictive models directly into their analytics and AI systems. MarketSignals, which now includes FanSignals™, GivingSignals™, and TravelSignals™, continues to offer the most comprehensive and actionable view of consumer behavior across the U.S. economy. Every signal is built through Wiland's proprietary, fully automated modeling platform that assembles and refines data inputs with unmatched speed, precision, and scale. To learn more about Brand and category signals or the MarketSignals platform, visit ABOUT WILAND, INC. Wiland, Inc. is the marketing data and audiences company that leading brands and nonprofit organizations trust to help them develop and maintain robust customer and donor relationships that produce higher revenue, less advertising waste, and more profit. Wiland's data and audience products are informed by the largest set of detailed, individual-level spending signals ever assembled. The company's AI-enabled response prediction platform analyzes this vast information to deliver powerful insights and solutions that drive success across all addressable marketing channels. For more information about Wiland, visit
Business Wire
4 hours ago
- Business Wire
Paired Power Secures Patent for PairTree™ Solar-Integrated EV Charger System
CAMPBELL, Calif.--(BUSINESS WIRE)-- Paired Power, a leading manufacturer of solar-powered electric vehicle (EV) charging systems, announced the award of U.S. Patent No. 12,375,024 for its innovative PairTree™ solar canopy solution. The patent, titled 'Solar canopy systems and methods,' formally recognizes Paired Power's proprietary approach to solar canopy installation, significantly expanding the deployment speed and accessibility of electric vehicle charging in situations with limited or no grid power. This marks the company's fourth patent since 2016, reinforcing its position as the innovator in solar powered EV charging. The newly patented technology covers a unique method for raising solar panels above a foundation using an integrated lift mechanism. Unlike conventional canopy installations that require elevated work, scaffolding, or external lifts, the PairTree™ system allows panels to be safely assembled at ground level before being elevated into place. This streamlined approach reduces installation time, labor costs, and safety risks, making deployment of EV charging infrastructure faster with fewer approval bottlenecks in a wider range of environments. "Securing this patent for PairTree is a monumental achievement for Paired Power," said Tom McCalmont, CEO of Paired Power. 'It embodies our commitment to making sustainable energy solutions more accessible, efficient, and deployable for everyone, everywhere. The ability to rapidly install solar canopies with minimal effort will accelerate the adoption of electric vehicles by providing charging options in previously underserved locations." PairTree reduces installation time from weeks to hours, enabling rapid deployment with immediate functionality and minimal site disruptions. Unlike traditional EV chargers that require trenching and major construction, PairTree preserves existing parking spaces and reduces or eliminates reliance on the grid during installation. Paired Power's signature combination of solar power and energy storage allows PairTree to create its own self-powered microgrid, further enhancing the solution's utility for remote, off-grid or utility-constrained locations. By generating and storing its own energy, the system also empowers operators to avoid costly demand charges often levied by utilities during peak energy use. Its modular, flexible design enables fast, cost-effective EV charger deployment where and when it's needed most. To learn more about the PairTree™ system, visit To delve further into the company's full suite of microgrid EV charging solutions, join Paired Power on Thursday, September 18, for a live webinar at 2:00pm EDT/11:00am PDT. About Paired Power: Trusted by cities, governments, and leading corporations, Paired Power manufactures solar-powered microgrid electric vehicle charger facilities (EVCF) that enable rapid deployment of new EV infrastructure without requiring expansions of existing grid capacity. Paired Power's flagship products are PairTree™, a microgrid solar powered EV charger that pairs a 4.6kW solar array with a 42.4 kWh Battery Energy Storage System (BESS) to provide Level 2 EV charging day or night, and PairFleet™, a larger microgrid designed to serve greater numbers of vehicle charging needs and can be customized based on a client's energy requirements. For more information about Paired Power, visit
Business Wire
5 hours ago
- Business Wire
Seek Labs Unveils Investigational, Equipment-Free Molecular Prototype for MTB on Rapid-Deploy SeekIt™ Platform
SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced a significant advancement in the global fight against tuberculosis (TB) with an investigational prototype for Mycobacterium tuberculosis (MTB) detection on its SeekIt™ platform. In internal analytical testing, the MTB SeekIt test delivered accurate results in under 60 minutes. Importantly, this innovation addresses a key limitation that has historically hindered effective TB diagnostics: breaking apart MTB's waxy, lipid-rich cell wall to gain access to detectable genetic material. In internal testing, SeekIt's proprietary chemical lysis step achieved this in just 15 minutes without heat, mechanical disruption, or complex lab tools and skilled operators. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. Share Seek Lab's MTB test demonstrates the speed, adaptability, and field-readiness of the modular SeekIt platform. All SeekIt's components—lysis chemistry, extraction, amplification, and detection—are proprietary to Seek Labs, exclusively discovered and developed in-house, and have been internally validated for performance and integration across multiple applications. The Global TB Testing Gap TB kills more than 1.25 million people each year, with nearly one in three cases going undiagnosed. In high-burden, resource-limited settings, centralized molecular tests face major hurdles: Pathogen complexity: MTB's waxy, lipid-rich cell wall has proven intractable to portable lysis methods for decades. Infrastructure dependence: Gold-standard molecular tests require expensive, power-intensive instruments, refrigeration, and highly skilled (or trained) operators. Sample limitations: Sputum collection is challenging for many patients and can deter testing. 'TB diagnostics have long been limited by gaps in both infrastructure and innovation that have often meant severe consequences for patient care and public health,' said Jared Bauer, CEO of Seek Labs. 'Our rapid, point-of-care SeekIt MTB test is designed to enable molecular-level detection in settings where access to equipment and electricity may be limited.' From Sample to Result: A Simplified Workflow At the core of the MTB SeekIt test is a proprietary, single-step chemical lysis buffer, involving a specially-formulated solution that disrupts MTB cells to release their genomic DNA. This breakthrough innovation takes just 15 minutes at room temperature, while competing methods (high-heat incubation or mechanical bead-beating) require longer times plus expensive equipment, specialized technicians, and complex infrastructure. More importantly, the integrated SeekIt test means the lysate itself flows seamlessly into SeekIt's downstream test components: Seek Extraction™ — A proprietary membrane-based binding system, developed and validated by Seek Labs, that rapidly captures MTB DNA without lab instruments. In validation testing, the MTB DNA yield for Seek Extraction was consistently more than 70% when compared to leading spin-column kits. Seek Amplification™ — A proprietary process that exponentially copies DNA at a constant temperature, detecting as few as 10 MTB genomic copies in 30 minutes without thermal cycling (internally validated), the conventional lab-based method. Molecular Lateral Flow Assay (mLFA) — A test strip that delivers clear, visual results in minutes indicating the presence of amplified DNA in a manner that can be optionally paired with the SeekIt mobile app for digital analysis and connectivity. Speed as a Strategy Conventional development of a molecular test for MTB can take a year or more. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. This rapid-deployment approach illustrates how SeekIt can be rapidly developed for numerous high-priority diseases in record time. 'This was more than a fast project; it's proof of our platform's flexibility,' said Kim Wirthlin, Chief Strategy Officer. 'By focusing our innovation on the MTB-specific lysis step for compatibility with our downstream isothermal amplification, we solved one of TB diagnostics' toughest technical challenges and produced a functional investigational prototype in a single quarter.' From Conference to Collaboration Seek Labs will debut the MTB SeekIt prototype at the 2025 Next Generation Dx Conference (August 18–20, 2025, Washington, D.C.), including: Podium Presentation — Enabling Point of Care Diagnostics Track, Tuesday, August 19 at 10:00 AM ET. Scientific Poster — Detailing the proprietary lysis chemistry, rapid development process, and validation data. Seek Labs is actively seeking partners across global health (ministries of health, TB-focused NGOs, and diagnostics distributors in high-burden regions such as sub-Saharan Africa and Southeast Asia) to advance the MTB SeekIt test through clinical validation, regulatory approval, and deployment. 'Innovation means nothing if it doesn't reach people,' said Bauer. 'We want to work with those who share our vision to advance development of accurate, accessible TB testing solutions wherever they're needed most.' About Seek Labs At Seek Labs, we don't wait for change—we build it. We're pursuing the breakthroughs the world can't wait for by developing programmable 'seek-and-destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release contains forward-looking statements, including statements regarding development timelines, clinical validation, regulatory pathways, and potential collaborations. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties—including scientific, regulatory, manufacturing, clinical, and commercial risks—that could cause actual results to differ materially. The MTB SeekIt assay is an investigational device. Limited by Federal law to investigational use.
